Lindsay A. Rosenwald, M.D., Executive Chairman of the Board of Directors
Dr. Rosenwald has served as our Executive Chairman of the Board of Directors since inception. Dr. Rosenwald has been a member of the Board of Directors of Fortress since October 2009 and has served as its Chairman, President and Chief Executive Officer since December 2013. Dr. Rosenwald also is Co-Portfolio Manager and Partner of Opus Point Partners LLC, an asset management firm in the life sciences industry, which he co-founded in 2009. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine.
Frank Taffy, J.D., Co-Founder, President, Chief Executive Officer and Director
Mr. Taffy has served as our President and Chief Executive Officer since June of 2015 (and since December of 2015, as a Director of the Board of Helocyte). Mr. Taffy has over fifteen years of experience in life sciences corporate development and business operations. He identified the Helocyte programs and co-founded the company during his role as Entrepreneur in Residence at Fortress Biotech. Mr. Taffy previously held the positions of Head (Senior Director) of Business Affairs at Forest Labs (now Allergan Plc) and Director of Corporate Development at Life Technologies (now Thermo Fisher Scientific), where he also held Board positions on behalf of the company. He also previously served as Vice President and General Counsel of Paramount Biosciences LLC, a global healthcare investment firm, where he led the formation and interim operation of a number of portfolio companies. Mr. Taffy started his career as Counsel for Intellectual Property at The Procter and Gamble Company. He holds a B.A. in biochemistry from the University of North Texas and a J.D. from Syracuse University College of Law.
David J. Horin, Interim Chief Financial Officer
Mr. Horin has been a Managing Partner of Chord Advisors, LLC (“Chord”) since June 2012. Chord provides accounting advisory services, SEC reporting advisory services, and IPO-readiness services. Pursuant to an agreement with Chord dated June 10, 2015, Mr. Horin is serving as our Interim CFO. While at Chord, Mr. Horin has gained extensive experience in financial accounting and SEC reporting for complex business transactions and issues arising from the application of existing or proposed financial accounting guidance. From March 2008 to June 2012, Mr. Horin was the Chief Financial Officer of Rodman & Renshaw Capital Group, Inc., a full-service investment bank dedicated to providing corporate finance, strategic advisory, sales and trading and related services to public and private companies across multiple sectors and regions. From March 2003 through March 2008, Mr. Horin was the Chief Accounting Officer at Jefferies Group, Inc., a full-service global investment bank and institutional securities firm focused on growth and middle-market companies and their investors. Prior to his employment at Jefferies Group, Inc., from 2000 to 2003, Mr. Horin was a Senior Manager in KPMG’s Department of Professional Practice in New York, where he advised firm members and clients on technical accounting and risk management matters for a variety of public, international and early growth stage entities. Mr. Horin has a Bachelor of Science degree in Accounting from Baruch College, City University of New York. Mr. Horin is also a Certified Public Accountant.
Elizabeth Clark Moore, M.S., Executive Vice President of Regulatory Affairs
Ms. Moore has served as our Executive Vice President of Regulatory Affairs since May 2015. She has over thirty years of experience in strategic regulatory registration and product development; management of FDA and global health authority interactions; and completion of regulatory and other due diligence for acquisition targets. Ms. Moore started her career at the National Institutes of Health (“NIH”), having served eight years with posts at both the National Institute of Allergy and Infectious Diseases and the National Cancer Institute. Her industry experience spans traditional pharmaceutical companies as well as biotech start-ups. Following her tenure at the NIH, Ms. Moore joined Agouron Pharmaceuticals as Director, Regulatory Affairs for Oncology Development. Subsequent to the Pfizer-Warner Lambert acquisition of Agouron, Ms. Moore was appointed Regulatory Affairs Site Head (Senior Director) of Pfizer Global R&D in La Jolla, CA. For the past fifteen years, Ms. Moore has directed global regulatory affairs strategy and operations for both public and private companies, holding senior-level positions at Coronado Biosciences (now Fortress), Paramount BioSciences, Tracon Pharmaceuticals, Salmedix (acquired by Cephalon), and most recently, Fate Therapeutics. Ms. Moore received her B.S. in Pharmacy from the University of Georgia and M.S. in Administrative Science from the Johns Hopkins University.